Anton Rx Report

How time flies!About three years ago Amazon jumped into the prescription business throwing a new monkey wrench in the segment. So, what’s happened in that

Were there fireworks to mark the event?Was there a parade to commemorate the long-awaited day?In short, NO! Annual Drug Trend Reports from Express Scripts (Evernorth)

The FDA approved a new infused specialty therapy last week, Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics, for the treatment of adult patients with relapsed or

We’ve ranted about the encroachment of hospital and health system owned specialty pharmacies more times that one can count. The growth of these organizations seemed

Last week the FDA approved a new specialty therapy, Jemperli (dostarlimab) from GlaxoSmithKline, for treating patients with recurrent or advanced endometrial cancer. Uterine cancers are

The article below details a new PSAO option for pharmacies, the ‘first’ PSAO for community-based specialty pharmacies from AmerisourceBergen named the Accelerate Specialty Network. Network

White bagging is back in the news and is increasingly being used by hospitals and health systems as a weapon to demonize emerging models for

So, when was the last time your company looked at its protocols to safeguard Protected Health Information (PHI)? You know, all that patient-specific information that

So, can you easily explain the differences between a chemically synthesized drug and a biologic?You might be surprised how difficult that has become. The article

We dog eared the article below some time ago but never got around to including it in a weekly Anton Rx Report. It is insightful